The Serum Institute in India CEO, Adar Poonawalla, said Thursday that the Serum Institute in India will try to release an Omicron-specific vaccine for COVID-19 after six months.
Speaking to reporters on the sidelines of the event, he said that there is good data available for the Covavax vaccine.
“The original Novavax vaccine, Kovovax, covers Omicron and there is good data for it. We will try to launch a vaccine specific to Omicron in six months,” he said.
The Pune-based Serum Institute is working with leading US biotech company Novavax to bring an Omicron vaccine.
The Omicron sub variant of COVID-19 has been declared as a variant of concern by the World Health Organization due to its rapid transmission and infection rate.
The company’s Covavax vaccine is available to those over the age of 12 in the country.
As for monkeypox, Mr Poonawala said the need for a vaccine was “debatable”.
“Yes, that made quite a bit of a stir when we saw the cases here. We’re doing research on this and we can collaborate with the biotechnology department on it as well. Our research is ongoing and we’ll see in six months,” he said.
(Except for the headline, this story has not been edited by the NDTV crew and is published from a syndicated feed.)